ArticleCirculation. Arrhythmia and electrophysiology2013
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator.
Article in Circulation. Arrhythmia and electrophysiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Wearable cardioverter defibrillator for transient arrhythmic risk and sudden cardiac death prevention: a systematic review and updated meta-analysis.Open heart · 2025Pooled it
- Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Systematic Review and Meta-Analysis.JACC. Clinical electrophysiology · 2019Pooled it
- Wearable Cardioverter-Defibrillator after Myocardial Infarction.The New England journal of medicine · 2018Trial
- Wearable Cardioverter-Defibrillator in Patients at Transient Risk of Sudden Cardiac Death: State of the Art and Contemporary Clinical Evidence.Diagnostics (Basel, Switzerland) · 2026Review
- A review on wearable cardioverter-defibrillators in clinical practice for sudden cardiac death prevention and heart failure management.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Review
- Wearable Technology in Cardiology: Advancements, Applications, and Future Prospects.Reviews in cardiovascular medicine · 2025Review
- The use of a wearable cardioverter defibrillator for a patient after coronary artery bypass grafting to protect against sudden cardiac death. The first case in Poland.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2024Article
- Article
- Revascularization and Left Ventricular Dysfunction for ICD Eligibility.Life (Basel, Switzerland) · 2023Review
- ANMCO position paper: guide to the appropriate use of the wearable cardioverter defibrillator in clinical practice for patients at high transient risk of sudden cardiac death.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Evaluation of transcutaneous near-infrared spectroscopy for early detection of cardiac arrest in an animal model.Scientific reports · 2023Article
- Commentary: Implantable or wearable cardioverter defibrillator after coronary artery bypass grafting in patients with left ventricular dysfunction?JTCVS open · 2023Article
- Evaluation of a Standardized Training and Adherence Surveillance Programme to Overcome Quality-of-Life Impairments and Enhance Compliance in Patients Treated with Wearable Cardioverter Defibrillator.Patient preference and adherence · 2023Article
- Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?Clinical research in cardiology : official journal of the German Cardiac Society · 2022Review
- Update on Wearable Cardioverter Defibrillator: A Comprehensive Review of Literature.Cardiology research · 2022Review
- Wearable cardioverter-defibrillators after myocardial infarction: a review of its clinical utility and unmet needs in current clinical practice.Cardiovascular intervention and therapeutics · 2022Review
- Multiparameter Monitoring with a Wearable Cardioverter Defibrillator.Sensors (Basel, Switzerland) · 2021Review
- Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter-Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction.Sensors (Basel, Switzerland) · 2021Article
- JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias.Journal of arrhythmia · 2021Article
- Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis.ESC heart failure · 2021Observational
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundImplantation of implantable cardioverter defibrillator for prevention of sudden cardiac death is deferred for 90 days after coronary revascularization, but mortality may be highest early after cardiac procedures in patients with ventricular dysfunction. We determined mortality risk in postrevascularization patients with left ventricular ejection fraction ≤35% and compared survival with those discharged with a wearable cardioverter defibrillator (WCD). METHODS AND
resultsHospital survivors after surgical (coronary artery bypass graft surgery) or percutaneous (percutaneous coronary intervention [PCI]) revascularization with left ventricular ejection fraction ≤35% were included from Cleveland Clinic and national WCD registries. Kaplan-Meier, Cox proportional hazards, propensity score-matched survival, and hazard function analyses were performed. Early mortality hazard was higher among 4149 patients discharged without a defibrillator compared with 809 with WCDs (90-day mortality post-coronary artery bypass graft surgery 7% versus 3%, P=0.03; post-PCI 10% versus 2%, P<0.0001). WCD use was associated with adjusted lower risks of long-term mortality in the total cohort (39%, P<0.0001) and both post-coronary artery bypass graft surgery (38%, P=0.048) and post-PCI (57%, P<0.0001) cohorts (mean follow-up, 3.2 years). In propensity-matched analyses, WCD use remained associated with lower mortality (58% post-coronary artery bypass graft surgery, P=0.002; 67% post-PCI, P<0.0001). Mortality differences were not attributable solely to therapies for ventricular arrhythmia. Only 1.3% of the WCD group had a documented appropriate therapy.
conclusionsPatients with left ventricular ejection fraction ≤35% have higher early compared to late mortality after coronary revascularization, particularly after PCI. As early hazard seemed less marked in WCD users, prospective studies in this high-risk population are indicated to confirm whether WCD use as a bridge to left ventricular ejection fraction improvement or implantable cardioverter defibrillator implantation can improve outcomes after coronary revascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.